Sign In
to Vote &
Create Storyboards.
 
Novartis reports efficacy of Signifor LAR for acromegaly after Phase III trial Sufferers of acromegaly, a rare condition often linked with gigantism, may soon have a new option for treatment as Novartis announced positive results of the final-phase trial of its Signifor LAR therapy.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard